Welcome to our dedicated page for Mountain Vy Md news (Ticker: MVMDF), a resource for investors and traders seeking the latest updates and insights on Mountain Vy Md stock.
Mountain Vy Md Inc (MVMDF) delivers innovative solutions across healthcare and diversified industries. This news hub provides investors with essential updates about corporate developments, strategic decisions, and market positioning.
Comprehensive Coverage: Access all official press releases alongside third-party analysis of financial results, partnership announcements, and operational milestones. Our curated feed eliminates the need to monitor multiple sources.
Key Focus Areas: Track updates on leadership changes, technology implementations, regulatory compliance, and growth initiatives. Content spans quarterly earnings disclosures, merger activity, and industry trend responses.
Staying Informed: Bookmark this page for streamlined access to MVMDF's evolving story. Check regularly for objective reporting that supports informed investment decisions.
Mountain Valley MD Holdings Inc. (MVMD) provided a business update on September 29, 2021, detailing advancements in oncology research, husbandry animal trials, and the development of its ivermectin formulations.
Key initiatives include expanded oncology trials for triple-negative breast cancer and melanoma, successful husbandry trials in Bangladesh with Ivectosol™ 1%, and the introduction of Ivectol™ for generic ivermectin production. The company plans commercialization in 2022 pending approvals. Shareholders approved board re-elections and an independent auditor but rejected a share consolidation proposal.
Mountain Valley MD Holdings Inc. has announced a letter of intent with Red White & Bloom Brands Inc. to establish a licensing agreement focused on cannabis product development. The agreement aims to leverage Mountain Valley's Quicksome™ technology for the formulation of cannabis products in Florida, Michigan, and California. Anticipated completion of the product development agreement is by October 2021, with provisions for research fees and royalties. This partnership is expected to validate Mountain Valley’s formulation technology in the expanding U.S. cannabis market.
Mountain Valley MD Holdings Inc. (MVMD) will hold its annual general and special meeting on September 21, 2021, at 11:30 a.m. ET. Shareholders will vote on key issues including a proposed continuance to Ontario and a share consolidation of up to ten existing shares for one new share. While the continuance aims to improve operational efficiency, it is not expected to affect the company’s business or assets. Shareholder approval is also sought for amending the stock option plan to comply with regulations of other potential stock exchanges in Canada.
Mountain Valley MD Holdings Inc. is set to upgrade its trading status from the OTCQB Venture Market to the OTCQX Best Market, effective August 27, 2021, under the symbol MVMDF. This transition reflects MVMD's compliance with elevated financial standards and corporate governance practices. The move is expected to enhance visibility among U.S. investors and improve share liquidity. The company is also reviewing options for further listings on the TSX Venture Exchange or NEO Exchange, aiming for greater exposure and institutional investor interest.
Mountain Valley MD Holdings Inc. (MVMDF) announces the appointment of Dr. Azhar Rana as Chief Medical Officer. Dr. Rana brings nearly two decades of experience in clinical development and medical affairs, including leadership roles at Bristol Myers-Squibb and AstraZeneca. His expertise will support MVMD's strategy in advancing its patented Quicksome™ and Quicksol™ technologies, aimed at enhancing drug delivery systems. The company granted Dr. Rana 1,000,000 stock options at $0.365 per share, vesting over five years. This strategic appointment is expected to propel MVMD's growth in health and wellness applications.
Mountain Valley MD Holdings Inc. (CSE: MVMD) announced the appointment of Gokul Kannan and Mark Gelnaw as advisors, aimed at enhancing its oncology research and technological applications. Kannan, a bioengineering expert, has significant research credentials, while Gelnaw brings over 35 years of financial and strategic experience. The company is also progressing a listing application for the TSX Venture Exchange or NEO Exchange, which could improve its market exposure. Additionally, the Company granted 3,725,000 stock options at an exercise price of $0.27, indicating strategic growth plans.
Mountain Valley MD Holdings Inc. (CSE: MVMD, OTCQB: MVMDF) announced positive results from a controlled cold chain evaluation of its Quicksome™ liposome technology for preserving the Trivalent Inactivated Poliovirus Vaccine (tIPV). IPV serotype two showed 100% preservation at 40°C for five days, surpassing WHO guidelines, while serotypes one and three achieved 50% preservation. The company aims to enhance this technology to achieve full compliance for all serotypes. Mountain Valley MD also signed a two-year research agreement with the FDA to further develop its cold chain technology.
Mountain Valley MD Holdings Inc. (MVMD) has announced significant advancements, including the approval of a patent for its Water Dissolvable Macrocyclic Lactone Cyclodextrin Complexes. This patent allows MVMD to enhance its solubilization technology, crucial for applications in human and animal health.
In partnership with a GMP production entity, MVMD's Ivectosol™ showed high yield in initial trials. Additionally, a collaboration with the FDA on a cold chain project aims to preserve vaccines under extreme conditions. MVMD also progresses in pre-clinical trials for cancers and tuberculosis, while exploring cannabis product formulations.
Mountain Valley MD Holdings Inc. (CSE: MVMD) has announced promising results from its BSL-4 lab COVID-19 study involving its solubilized Ivermectin technology, Ivectosol™. The study demonstrated that a dose of 2.5 mg/kg effectively cleared the B.1.1.7 variant, with in vitro tests confirming antiviral activity against other variants. The company is now advancing to phase one human trials focusing on efficacy and safety of Ivectosol™ sublingual wafers. The breakthrough study marks a significant validation of Ivectosol™ in combating COVID-19 variants.
Mountain Valley MD Holdings Inc. (MVMDF) has announced the filing of a novel cancer adjuvant patent and the initiation of pre-clinical trials for Ivectosol™ targeting triple-negative breast cancer, metastatic melanoma, and lung carcinoma. The company aims to leverage the anti-cancer properties of ivermectin, demonstrated in previous studies, to enhance current chemotherapy and immunotherapy protocols. The first results from these trials are anticipated by the end of June 2021.
